Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.96 |
| ▸ | HRH1 | P35367 | 1/20 | 0.77 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.66 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.66 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19661490 | 1.00 | HRH3 (0.96) | HRH3HRH1SIGMAR1L3MBTL1MBTD1 | |
| SCHEMBL20820999 | 1.00 | HRH3 (0.96) | HRH3HRH1SIGMAR1L3MBTL1MBTD1 | |
| SCHEMBL18923722 | 1.00 | HRH3 (0.96) | HRH3HRH1SIGMAR1L3MBTL1MBTD1 | |
| SCHEMBL19661165 | 1.00 | HRH3 (0.96) | HRH3HRH1SIGMAR1L3MBTL1MBTD1 | |
| SCHEMBL19661488 | 1.00 | HRH3 (0.96) | HRH3HRH1SIGMAR1L3MBTL1MBTD1 | |
| SCHEMBL13164030 | 0.98 | HRH3 (1.00) | HRH3HRH1SIGMAR1L3MBTL1MBTD1 | |
| SCHEMBL25093149 | 0.94 | HRH3 (0.86) | HRH3HRH1SIGMAR1L3MBTL1MBTD1 | |
| SCHEMBL10211758 | 0.94 | HRH3 (0.92) | HRH3HRH1SIGMAR1L3MBTL1MBTD1 | |
| SCHEMBL25092863 | 0.92 | HRH3 (0.89) | HRH3HRH1SIGMAR1L3MBTL1MBTD1 | |
| SCHEMBL13271136 | 0.89 | HRH1 (0.90) | HRH3HRH1SIGMAR1L3MBTL1MBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4140485-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | Gilead Sciences, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| US-10442812-B2 | Substituted 4-methyl-pyrrolo[1,2-a]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity | NORTHWESTERN UNIVERSITY (US) | 2019-10-15 | — | — | US | disclosed |
| US-20190152980-A1 | SUBSTITUTED 4-METHYL-PYRROLO[1,2-A]PYRIMIDINE-8-CARBOXAMIDE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY | NORTHWESTERN UNIVERSITY (US) | 2019-05-23 | — | — | US | disclosed |
| US-10227352-B2 | Substituted 4-methyl-pyrrolo[1,2-A]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity | NORTHWESTERN UNIVERSITY (US) | 2019-03-12 | — | — | US | disclosed |
| US-10040799-B2 | Substituted 4-methyl-pyrrolo[1,2-A]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity | NORTHWESTERN UNIVERSITY (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180037586-A1 | SUBSTITUTED 4-METHYL-PYRROLO[1,2-A]PYRIMIDINE-8-CARBOXAMIDE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY | NORTHWESTERN UNIVERSITY (US) | 2018-02-08 | — | — | US | disclosed |
| US-9802942-B2 | Substituted 4-methyl-pyrrolo[1,2-A]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity | NORTHWESTERN UNIVERSITY (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| US-RE46511-E1 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD. (KR) | 2017-08-15 | — | — | US | disclosed |
| US-9700559-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2017-07-11 | — | — | US | disclosed |
| US-7737149-B2 | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2010-06-15 | — | — | US | disclosed |
| US-20090203673-A1 | 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-13 | — | — | US | disclosed |
| US-20090156591-A1 | Thiophene and Thiazole Substituted trifluoroethanone Derivatives as Histone Deacetylase (Hdac) Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-06-18 | — | — | US | disclosed |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-7384952-B2 | Pyrazolopyrimidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-10 | — | — | US | disclosed |
| US-7384952-B2 | Pyrazolopyrimidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-10 | — | — | US | disclosed |
| EP-1926721-A2 | THIOPHENE AND THIAZOLE SUBSTITUTED TRIFLUOROETHANONE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2008-06-04 | — | — | EP | disclosed |
| EP-1857459-A2 | Pyrazolopyrimidine compound and a process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 2007-11-21 | — | — | EP | disclosed |
| CN-1989119-A | New benzoyl urea derivatives | RICHTER GEDEON VEGYESZET (HU) | 2007-06-27 | — | — | CN | disclosed |
| WO-2007029035-A2 | THIOPHENE AND THIAZOLE SUBSTITUTED TRIFLUOROETHANONE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10040799-B2 | Substituted 4-methyl-pyrrolo[1,2-A]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity | GBA1, GBA2, GBA3 | HRH3 3401/4885HRH1 2582/4885SIGMAR1 2576/4885 |
| US-20090156591-A1 | Thiophene and Thiazole Substituted trifluoroethanone Derivatives as Histone Deacetylase (Hdac) Inhibitors | HDAC1, HDAC2, HDAC11 | HRH3 934/4885HRH1 1814/4885SIGMAR1 2850/4885 |
| US-10227352-B2 | Substituted 4-methyl-pyrrolo[1,2-A]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity | GBA1, GBA2, GBA3 | HRH3 3401/4885HRH1 2582/4885SIGMAR1 2576/4885 |
| US-20180037586-A1 | SUBSTITUTED 4-METHYL-PYRROLO[1,2-A]PYRIMIDINE-8-CARBOXAMIDE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY | GBA1, GBA2, GBA3 | HRH3 3401/4885HRH1 2582/4885SIGMAR1 2576/4885 |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | HDAC1, HDAC11, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HRH3 1893/4885HRH1 1543/4885SIGMAR1 1976/4885 |
| US-20190152980-A1 | SUBSTITUTED 4-METHYL-PYRROLO[1,2-A]PYRIMIDINE-8-CARBOXAMIDE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY | GBA1, GBA2, GBA3 | HRH3 3401/4885HRH1 2582/4885SIGMAR1 2576/4885 |
| US-20170260143-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | HRH3 3902/4885HRH1 2861/4885SIGMAR1 1440/4885 |
| US-10442812-B2 | Substituted 4-methyl-pyrrolo[1,2-a]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity | GBA1, GBA2, GBA3 | HRH3 3401/4885HRH1 2582/4885SIGMAR1 2576/4885 |
| US-20090203673-A1 | 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | CCNI, MKI67, CCNA1 | HRH3 334/4885HRH1 119/4885SIGMAR1 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.